Total delivery costs are lower-and rates of vaginal delivery higher-when external cephalic version (ECV) is done with versus without neuraxial anesthesia. So say the results of a study by Stanford University researchers published online in Anesthesia & Analgesia.
Total delivery costs are lower-and rates of vaginal delivery higher-when external cephalic version (ECV) is done with versus without neuraxial anesthesia. So say the results of a study by Stanford University researchers published online in Anesthesia & Analgesia.
The new research was based on national data on the cost of ECV with and without anesthesia and costs of vaginal and cesarean deliveries and from previous comparisons of ECV success rates with and without anesthesia. The investigators analyzed the data using a computer cost model, which considers possible outcomes and probability uncertainties at the same time.
Using anesthesia increased average success rates for ECV from 38% (individual study range 31% to 58%) to 60% (individual study range 44% to 87%). Because it led to fewer cesareans, anesthesia also decreased total delivery cost by an average of $276 (range $720 savings to $112 additional cost). Mean expected total delivery costs-including the cost of attempting/performing ECV with anesthesia-were $8,931 (range $8,541 to $9,252) versus $9,207 (range $8,896 to $9,419) without anesthesia.
The researchers concluded that increased ECV success with neuraxial anesthesia and the subsequent reduction in breech cesarean delivery rate offset the costs of providing anesthesia to facilitate ECV. The reason for the increased success rates ECV, said lead author Brendan Carvalho, MD, may be that muscle relaxation triggered by anesthesia allows practitioners to apply less pressure when performing the procedure.
Maternal sFLT1 and EDN1 linked to late-onset preeclampsia
November 25th 2024A new study highlights the association of maternal soluble Fms-like tyrosine kinase 1 and endothelin 1 with preeclampsia severity, offering insights into the pathogenesis of early- and late-onset forms of the condition.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More